When you buy through links on our articles, Future and its syndication partners may earn a commission.

In a report released today, Matthew Biegler from Oppenheimer maintained a Hold rating on Fate Therapeutics (FATE – Research Report). The company’s shares closed yesterday at $2.38. According to ...

Speaking with Variety at the Thessaloniki Film Festival, where the "Act of Killing" director's first fiction feature, "The ...

Brian Nagel, Oppenheimer senior analyst, joins 'Squawk Box' to break down Home Depot's Q3 earnings results. Posted: November ...

In a report released today, Matthew Biegler from Oppenheimer maintained a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), with a price target of $15.00. The company’s shares closed ...

Greece’s Thessaloniki Film Festival ends this evening with a screening of The End, the latest feature project from the ...

Oppenheimer has become the latest Wall Street firm to raise its year-end price target for the S&P 500. Chief Market Strategist John Stoltzfus said in a report shared with MarketWatch on Monday that ...

Oppenheimer upgrades MoneyLion to Outperform as it benefits from lower interest rates, easing regulations, and potential ...

Oppenheimer's Limited-Edition Steelbook releases November 19 and comes with 4K and standard Blu-ray discs as well as a ...

Murphy tells IndieWire about playing a man who, in 1985, unearths awful discoveries at the local Irish convent — something ...

Cillian Murphy didn’t read “Small Things Like These” looking for a film to do. He was simply a fan of the author, Claire ...